LiliumX is Valink Therapeutics' platform for discovering bispecific antibody-drug conjugates.
View competitorsValink Therapeutics, founded with a mission to revolutionize cancer treatment, focuses on developing next-generation antibody-based therapeutics. The company specializes in discovering bispecific antibody drug-conjugates (BsADC) targeting solid tumors that are poorly addressed by current immunotherapies. By incorporating multiple antibody modifications simultaneously, Valink Therapeutics rapidly and scalably generates complex drug candidates with bi-/multispecificity, multivalency, and drug-conjugation.
Notable figures affiliated with Valink Therapeutics include leading scientists and industry experts in oncology and biotechnology. The company has secured investments from prominent venture capital firms specializing in life sciences. Key achievements include the successful identification of novel mechanisms of action from known targets and the development of promising therapeutic candidates. Valink Therapeutics' innovative approach has the potential to significantly impact the treatment landscape for solid tumors, offering new hope for patients with limited options.
Valink Therapeutics' most recent funding round was for $125k (USD) in January 2021.
As of Jan 1, 2021, Valink Therapeutics has disclosed funding of $125k (USD).

LiliumX
liliumx.com

Rondo Therapeutics
rondotx.com

Velorum Therapeutics
velorumtx.com

Adventris Pharmaceuticals
adventris.com

Valitor
valitorbio.com
Revelio Therapeutics

Catena Biosciences

Eris Biotech
erisbio.com

Tradewind BioScience
tradewindbio.com

Solve Therapeutics
solvetx.com

Aarvik Therapeutics
aarviktx.com
Soteria Biotherapeutics

Asher Bio
asherbio.com

Serinus Biosciences
serinus.bio

Shasqi
shasqi.com

GV20 Therapeutics
gv20tx.com

Paramita Therapeutics

Adcentrx Therapeutics
adcentrx.com

OnCusp Therapeutics
oncusptx.com

Resonant Therapeutics
resonantrx.com